9 results
Primary Objective: To assess the effect of esomeprazole on the pharmacokinetics of BMS-275183. Secondary Objectives: To evaluate the safety and efficay of BMS-275183 co-administered with esomeprazole.
Core:Core Primary Objective:* To investigate the safety and tolerability of OMO-1 when given orally to patients with locally advanced, unresectable or metastatic solid malignancies, alone or in combination with anti-cancer treatments, and define the…
Primary objective is to evaluate the area under the plasma concentration-time curve (AUC) of capecitabine alone, compared to capecitabine used with esomeprazole and compared to capacitabine used with esomeprazole and the acid beverage Coca-Cola in…
Primary objective:To evaluate the area under the curve of afatinib compared to afatinib concomitantly used with esomeprazole and to afatinib used with esomeprazole 3 hours prior in patients with non-small cell lung cancer.Secondary objective:1.…
To determine the influence of esomeprazole on the AUC of regorafenib in patients with mCRC or GIST.
In this study we want to determine the erlotinib concentrations in blood after administration of erlotinib with water or whole milk with and without an antacid .
Efficacy and safety.
To determine the influence of the acidic beverage Coca-Cola, concomitantly taken with erlotinib (with or without a PPI), on erlotinib plasma pharmacokinetics compared to erlotinib concomitantly taken with water in cancer patients.
Elinzanetant is an investigational compound. It is not approved for sale. That means it can only be used in studies like this one. Elinzanetant has been extensively tested in the laboratory. It has also been already administered to approximately 300…